Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BIRC2 | Q13490 | 5/20 | 0.56 |
| ▸ | MMP3 | P08254 | 12/20 | 0.46 |
| ▸ | MMP1 | P03956 | 9/20 | 0.46 |
| ▸ | MMP2 | P08253 | 8/20 | 0.46 |
| ▸ | MMP7 | P09237 | 3/20 | 0.46 |
| ▸ | MMP9 | P14780 | 3/20 | 0.46 |
| ▸ | MMP14 | P50281 | 1/20 | 0.42 |
| ▸ | Q9HBH1 | 1/20 | 0.41 | |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Actinonin SCHEMBL279450 | 1.00 | BIRC2 (0.56) | BIRC2MMP3MMP1MMP2MMP7 | |
| Actinonin SCHEMBL279122 | 1.00 | BIRC2 (0.56) | BIRC2MMP3MMP1MMP2MMP7 | |
| Actinonin SCHEMBL14490676 | 1.00 | BIRC2 (0.56) | BIRC2MMP3MMP1MMP2MMP7 | |
| Actinonin SCHEMBL123273 | 1.00 | BIRC2 (0.56) | BIRC2MMP3MMP1MMP2MMP7 | |
| SCHEMBL6294118 | 0.97 | BIRC2 (0.55) | BIRC2MMP3MMP1MMP2MMP7 | |
| SCHEMBL18328823 | 0.92 | MMP3 (0.49) | BIRC2MMP3MMP1MMP2MMP7 | |
| SCHEMBL21387112 | 0.92 | BIRC2 (0.47) | BIRC2MMP3MMP1MMP2MMP7 | |
| SCHEMBL14279424 | 0.90 | BIRC2 (0.55) | BIRC2MMP3MMP1MMP2MMP7 | |
| SCHEMBL6294172 | 0.87 | BIRC2 (0.58) | BIRC2MMP3MMP1MMP2MMP7 | |
| SCHEMBL9495973 | 0.87 | BIRC2 (0.44) | BIRC2MMP3MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011076854-A1 | CLEAVAGE OF β-AMYLOID PRECURSOR PROTEIN | PROBIODRUG AG (DE) | 2011-06-30 | — | — | WO | disclosed |
| US-20110152341-A1 | CLEAVAGE OF B-AMYLOID PRECURSOR PROTEIN | PROBIODRUG AG (DE) | 2011-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152341-A1 | CLEAVAGE OF B-AMYLOID PRECURSOR PROTEIN | MEP1B, MEP1A, APP | BIRC2 105/4885MMP3 1361/4885MMP1 2631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.